We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Urine Circulating Anodic Antigen Test Diagnoses Schistosomiasis

By LabMedica International staff writers
Posted on 27 May 2015
An accurate diagnosis is essential and should be adapted to the specific stage of a schistosomiasis control program and parasitological methods to detect Schistosoma eggs in stool are widely used.

These conventional parasitological methods are insensitive for the detection of light-intensity infections and techniques with high sensitivity and specificity are required for an accurate diagnosis in low-transmission settings and verification of elimination.

An international team of scientists led by those at the Swiss Tropical and Public Health Institute (Basel, Switzerland) collected a total of 1,740 urine samples in 2013 from children on Pemba Island (Tanzania). The children attended schools where the S. haematobium prevalence was less than 2%, 2% to 5%, and 5% to 10%, based on a single urine filtration. On the day of collection, all samples were tested for microhematuria with reagent strips and for the presence of S. haematobium eggs with microscopy.

The team determined the accuracy of a urine-based up-converting phosphor-lateral flow circulating anodic antigen (UCP-LF CAA) assay on 1,200 samples eight months later, while urine filtration slides were subjected to quality control (QCUF). In the absence of a true “gold” standard, the diagnostic performance was calculated using latent class analyses (LCA). The UCP-LF CAA designated UCAA2000 is currently considered to show the best trade-off between a high sensitivity and convenient field applicability.

The “empirical” S. haematobium prevalence revealed by UCP-LF CAA, QCUF, and reagent strips was 14%, 5%, and 4%, respectively. LCA revealed a sensitivity of the UCP-LF CAA, QCUF, and reagent strips of 97%, 86%, and 67% respectively. Test specificities were consistently above 90%. Since QCUF revealed more S. haematobium-infected individuals than the initial urine filtration microscopy, only QCUF results were considered for the calculation of sensitivity and specificity. There was a significant relationship between circulating anodic antigen CAA pg/mL levels and S. haematobium egg counts, between CAA pg/mL levels and microhematuria grading, and between egg counts and microhematuria grading.

The authors concluded that the UCAA2000 as a suitable tool for large-scale monitoring of urogenital schistosomiasis in control programs in low-endemicity settings targeting elimination and for surveillance in areas that achieved elimination. For surveillance at a smaller scale, including testing of suspected cases in remote public health care centers without laboratory equipment, a simple-to-use but still highly sensitive point-of-care-CAA rapid test is highly desirable. The study was published on May 14, 2015, in the journal Public Library of Science Neglected Tropical Diseases.

Related Links:

Swiss Tropical and Public Health Institute 



Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Dermatophytosis Rapid Diagnostic Kit
StrongStep Dermatophytosis Diagnostic Kit
New
Silver Member
ACTH Assay
ACTH ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.